River Vision Development

Horizon Pharma to acquire River Vision Development

Wednesday, May 10, 2017

Horizon Pharma, a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, has agreed to acquire River Vision Development and its development-stage medicine teprotumumab (RV001), a fully human monoclonal antibody (mAb) currently in development for thyroid eye disease (TED), a rare, autoimmune inflammatory disorder.

[Read More]